Compare YORW & PRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | YORW | PRTC |
|---|---|---|
| Founded | 1816 | 2015 |
| Country | United States | United States |
| Employees | 104 | N/A |
| Industry | Water Supply | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 472.0M | 464.3M |
| IPO Year | 1994 | N/A |
| Metric | YORW | PRTC |
|---|---|---|
| Price | $30.20 | $15.39 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 126.0K | 3.4K |
| Earning Date | 03-03-2026 | 04-29-2026 |
| Dividend Yield | ★ 2.99% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.39 | N/A |
| Revenue | ★ $77,488,000.00 | N/A |
| Revenue This Year | $11.78 | N/A |
| Revenue Next Year | $4.95 | N/A |
| P/E Ratio | $21.92 | ★ $8.09 |
| Revenue Growth | ★ 3.37 | N/A |
| 52 Week Low | $29.68 | $13.30 |
| 52 Week High | $36.48 | $20.00 |
| Indicator | YORW | PRTC |
|---|---|---|
| Relative Strength Index (RSI) | 35.52 | 33.39 |
| Support Level | $30.02 | $14.50 |
| Resistance Level | $32.98 | $18.10 |
| Average True Range (ATR) | 0.68 | 0.41 |
| MACD | -0.08 | -0.09 |
| Stochastic Oscillator | 20.72 | 14.29 |
The York Water Co is an investor-owned water utility company in the United States. The primary business of the company is to impound, purify to meet or exceed safe drinking water standards and distribute water. It also owns and operates three wastewater collection systems and eleven wastewater collection and treatment systems. The company operates within its franchised territory, which covers more than 57 municipalities within four counties in south-central Pennsylvania.
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.